The OncLive Brain Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of brain cancer, including glioma, glioblastoma multiforme, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.
Dr. Lukas on Immunotherapy in GlioblastomaOctober 26th 2016
Rimas V. Lukas, MD, associate professor of Neurology, director, Medical Neuro-Oncology, University of Chicago Medicine, discusses some of the exciting advances recently seen with immunotherapy in the treatment of patients with glioblastoma
Computer Simulation Helps Plan Transducer Placement in GlioblastomaOctober 13th 2016
For patients who are likely to experience contiguous recurrence of glioblastoma, a new computer simulation using tumor treating fields and employing a personalized transducer array, delivered electric field intensities that exceeded therapeutic intensities in 3 different tumor locations. The findings may aid treatment planning when using the NovoTAL System, which optimizes therapeutic delivery in 2 orthogonal directions to the gross tumor volume and proximal peri-tumoral brain zone.
Early Promise of Radiation Plus PCV in Patients With Low-Grade GliomaAugust 19th 2016
Erica Bell, PhD, assistant professor-Clinical, Ohio State University Comprehensive Cancer Center, discusses a mutational analysis examining radiation therapy plus procarbazine, CCNU, and vincristine (PCV) as a potential treatment for patients with high-risk, low-grade glioma.
Models Pave the Way for Improved Outcomes in MedulloblastomaAugust 16th 2016
To discover targeted therapies for the more common and severe types of medulloblastoma, a laboratory at Sanford Burnham Prebys Medical Discovery Institute has led efforts to develop genetically engineered mouse models and patient-derived xenografts for studying the molecular basis of the disease.
Dr. van den Bent on Adjuvant Temozolomide in Anaplastic GliomaJuly 27th 2016
Martin J. Van Den Bent, MD, professor, Neuro-Oncology, Erasmus MC-Daniel den Hoed Cancer Center, the Netherland, discusses the results of an interim analysis of the randomized phase III CANTON trial, which investigated concurrent and adjuvant temozolomide in patients with anaplastic glioma without a 1p/19q co-deletion.
Dr. Reardon on Nivolumab/Ipilimumab in GlioblastomaJune 7th 2016
David A. Reardon, MD, discusses results of a cohort from the open-label CheckMate-143 trial, which explored the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with recurrent glioblastoma multiforme (GBM).
Survival in Recurrent GBM Surpasses Historical Results with Gene Therapy
A novel antiangiogenic gene therapy, added to bevacizumab, led to significantly better overall survival in recurrent glioblastoma multiforme compared with historical patients treated with bevacizumab alone, a small phase II trial showed.
Adding Temozolomide to Radiotherapy Is Effective and Tolerable in Older Adults With GlioblastomaJune 5th 2016
Adding temozolomide to short-course radiotherapy after surgery boosted overall survival by nearly 2 months, bringing 1-year survival rates up from 22.2% to 37.8% for elderly patients with glioblastoma.
Temozolomide Trial Shows Improved 5-Year Survival Rates in Anaplastic GliomaJune 4th 2016
Results from a phase III trial investigating the benefit of adjuvant temozolomide in combination with radiation therapy has the potential to be practice changing for a rare type of brain cancer.